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Background/aim: Mucopolysaccharidoses (MPS) are a group of hereditary metabolic diseases. The aim of this study was to share the
previously unreported calvarial finding of internal hypertrophy of the occipitomastoid sutures (IHOMS) together with some other wellknown cranial MRI findings in this patient series.
Materials and methods: A retrospective evaluation was conducted of 80 cranial MRIs of patients who had been diagnosed and followed
up with MPS from 2008 to 2019 in our center. Of these patients, 11 had Hurler, 14 had Hunter, 24 had Sanfilippo, 15 had Morquio, 14
had Maroteaux–Lamy, and 2 had Sly disease. The cranial MRIs were assessed in two main groups as parenchymal intradural cranial MRI
findings and extradural calvarial findings.
Results: The most common parenchymal intradural cranial MRI findings were white matter signal alterations (n = 51, 63%) and
perivascular space enlargements (n = 39, 48%). The most common extradural calvarial findings were J-shaped sella (n = 45, 56%) and
tympanic effusion (n = 44, 55%). Although IHOMS was defined in a relatively small number of the patients (n = 12, 15%), the prevalence
rate was high in MPS type I (n = 6, 54%).
Conclusion: The abnormal cranial MRI findings of the MPS patients, including the newly identified IHOMS, may provide diagnostic
clues to differentiate the type of the disease in radiological imaging.
Key words: Lysosomal storage diseases, glycosaminoglycans, mucopolysaccharidosis, magnetic resonance imaging, internal hypertrophy
of the occipitomastoid sutures

1. Introduction
Lysosomal storage diseases (LSDs) are a group of congenital
metabolism errors. They are caused by the accumulation
of macromolecules (proteins, polysaccharides, and lipids)
due to defects of the enzymes needed for the breakdown
of these macromolecules. The substrate accumulation
in macrophages or connective tissue cells affects various
systems of the body. Mucopolysaccharidoses (MPS)
constitute one of the most prevalent subgroups of LSDs,

in which the enzymatic defects cause glycosaminoglycans
(GAGs) (also called mucopolysaccharides) to accumulate
in the skeletal system, cornea, heart, vasculature, and
several other organ systems. The GAG fragments increase
in the fluids of the body (urine, blood, and cerebral spinal
fluid) [1–3].
There are 7 different well-defined types of MPS and
some of these also have subtypes (MPS type I: Hurler
disease, MPS type II: Hunter disease, MPS type III:
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Sanfilippo disease, MPS type IV: Morquio disease, MPS
type VI: Maroteaux–Lamy disease, MPS type VII: Sly
disease, MPS type IX). Except for MPS type II disease,
which has an X-linked recessive inheritance, all other
MPS types are transmitted in an autosomal recessive
fashion. Patients with MPS generally look normal at
birth and they may lack the characteristic features of the
disease at that time. However, they are often affected by
an abnormal, multisystemic, progressive developmental
process that varies according to the type and the severity of
the disease. As a result, a variety of skeletal manifestations
called dysostosis multiplex (DMX) and extraskeletal
manifestations with some phenotypic abnormalities
peculiar to MPS occur clinically [1–3].
Although the involved enzymes and the substances
accumulated due to their deficiencies have been clearly
specified for each type of MPS, the mechanisms resulting
in disease symptoms, especially for skeletal manifestations,
have not been clearly identified. Skeletal symptoms
usually appear first in most MPS, except for MPS type
III, in which skeletal symptoms become apparent later
after other system manifestations, mainly in the central
nervous system (CNS). They generally occur due to the
effects of the primary catabolic defect in the bones and
cartilage. The skeletal manifestations of MPS depend
on the type of the disease and include short stature,
atlantoaxial instability (especially in MPS type IV), spinal
deformations (gibbus deformity, scoliosis, kyphosis, and
platyspondyly), spinal cord compression, joint stiffness
and contractures, joint laxity (specific to MPS type IV),
macrocephaly, hip dysplasia, valgus deformity of the
knees, chest deformity, and joint effusions. MPS type
III is characterized by fewer skeletal abnormalities that
are accompanied by severe neurological manifestations.
The radiological features of DMX include J-shaped sella
turcica, calvarial thickening, shortening of the sternum,
broad and short clavicles, platyspondyly, inferiorly beaked
vertebrae, dysplastic odontoid process, round iliac wings,
hip dysplasia, proximal pointing of short and hypoplastic
metacarpals, and hypoplastic thick and short epiphyses
of the long bones. Other expected clinical manifestations
of MPS include coarse facial features, short stature,
arthropathy, visceromegaly, cataracts, and psychomotor
retardation [1,4–8].
In the present study, an overview is presented of the
most frequent cranial MRI findings of MPS types. Enzyme
deficiencies, accumulated metabolites, the presence of
DMX, and the main clinical findings are summarized in
Table 1 [1,3,7–11].
The aim of our study was to share some prominent
cranial MRI findings of different MPS types and to show an
unreported calvarial finding of posterior fossa in addition
to some other well-known MRI findings in patients with
MPS.

2. Patients and methods
The definitive diagnosis of MPS was based on a positive
family history and the presence of specific phenotypic and
clinical features, determination of elevated GAG levels in
urine samples and skeletal surveys positive for DMX, and
enzymatic analyses for the detection of specific enzyme
deficiencies and identification of the type of the disease.
All patients who had been diagnosed with MPS between
2008 and 2019 at our institution’s Division of Pediatric
Metabolism were retrospectively identified from the
electronic database of patient records.
Of these, 80 patients (male and female) who had
pretreatment baseline MRIs of the cranium were included
in the present study. Most of the cranial MRI scans were
performed in our institution. Some of the patient MRIs
recorded in our picture archiving and communication
system (PACS) were performed in different centers or
institutions.
Eleven patients in this study had Hurler disease (type
I), 14 had Hunter disease (type II), 24 had Sanfilippo
disease (type III), 15 had Morquio disease (type IV), 14
had Maroteaux–Lamy disease (type VI), and 2 had Sly
(VII) disease. At the time of the MRI examinations, patient
ages ranged between 1 month and 19 years, with a mean
age of 8 years. Some of the patients with type I, II, and
VI diseases were in good mental condition, and received
enzyme replacement therapies periodically.
Through the PACS, the cranial MRIs of a total of 80
patients were reviewed retrospectively. The radiological
assessment and measurements were performed with the
consensus of two radiologists, each with more than 5 years
of neuroradiology experience who were blinded to the
type of disease.
Although the images were taken on different 1.5 Tesla
MRI machines, all the cranial MRI examinations included
basal sequences. Cranial MRI examinations included
axial 3-mm-thick spin echo T1-weighted (232 × 320
matrix, TE/TR: 11/447), T2-weighted 261 × 320 matrix,
TE/TR: 113/4540), FLAIR (217 × 320 matrix, TE/TI/TR:
92/2500/9000), sagittal 4-mm-thick T1-weighted (248 ×
320 matrix, TE/TR: 10/390), and coronal 4-mm-thick T2weighted (254 × 384 matrix, TE/TR: 95/5690) sequences.
The assessment of the cranial MRI findings was
performed by categorizing the findings into 2 groups. One
group of findings included the intradural and parenchymal
abnormalities, while the other group included the
extradural and calvarial changes. The specific imaging
findings evaluated under the heading of each group were
as follows:
Group I. MRI findings of intradural and parenchymal
changes: parenchymal atrophy, hydrocephalus, white
matter signal alterations (WMSAs), perivascular space
(Virchow–Robin space) enlargements (PVSEs) in the peri-

1049

DAMAR et al. / Turk J Med Sci
Table 1. Summary of the important features of the MPS types.

Disease type

Deficient enzyme

Accumulated Radiographic and clinical findings
metabolites
DMX SS CFF
OM JS
CRD

H
Type I (Hurler)

HS/S

Type II (Hunter) severe/mild

Type III
(Sanfilippo)

Type IV
(Morquio)

+

+

+

+

+

+

Alpha-L-iduronidase

hs, ds

Patient exhibits these findings moderate
(HS)+/mild(S)+

Iduronate sulfatase

hs, ds

+

hs

ks, cs

A

Heparan sulfamidase

B

N-acetylglucosaminidase

C

Acetyl-CoA: alphaglucosaminide
Acetyltransferase

D

N-acetylglucosamine
6-sulfatase

A

Galactose-6-sulfate
sulfatase

B

Beta-galactosidase

Type VI (Maroteaux–Lamy)

N-acetylgalactosamineds
4-sulfatase

Type VII (Sly)

Beta-glucuronidase

hs, ds, cs

+

+

+

+

+

CC

MR

+

+
+/- !

-

+/-

Patient exhibits these findings -/mild +

-

+~

+

+#

-/+

-/+

+*

+

+

-!

+

+

+

+

+

+

+

-!

+

+

-/+

+

+

+

+

-/+

H: Hurler, HS: Hurler–Schie, S: Schie, hs: Heparan sulfate, ds: Dermatan sulfate, ks: Keratan sulfate, cs: Chondroitin sulfate, DMX:
Dysostosis multiplex, SS: Short stature (#: evident due to platyspondyly), CFF: Coarse facial features, OM: Organomegaly (hepatomegaly
and/or splenomegaly), JS: Joint stiffness (*: stiffness and laxity), CRD: Cardiorespiratory disorders, CC: Corneal clouding, MR: Mental
retardation [!: patients exhibit normal intelligence with MPS type 1 S (Schei), type IV, and type VI], ~: Mental retardation and/or
hyperactivity

supraventricular white matter and corpus callosum, optic
nerve sheath enlargement (uni-/bilaterally).
For statistical evaluation, the patients who had type
I, II, and VI diseases were divided into three age groups.
The first group comprised patients aged ≤2 years, the
second group patients were aged 2–10 years, and the third
group patients were older than 10 years. The number of
the PVSEs in the peri-supraventricular white matter and
corpus callosum were also categorized in 3 groups as ≤5,
5–10, and >10.
The Evans ratio was used to define the presence of
hydrocephalus and a value of ≥0.30 was accepted as
positive for the presence of ventriculomegaly.
Parenchymal atrophy was accepted as present when
extensive widening of the Sylvian fissures, brain sulci,
and enlargement of other peripheral subarachnoid spaces
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were observed. Due to the presence of accompanying
hydrocephalus in some cases and the presence of
morphological asymmetry of sulci and fissures, no
measuring systems were used for the scoring of the sulcal
widening or subarachnoid space enlargement. Thus, the
atrophic changes were subjectively assessed in consensus,
as present or absent.
Group II. MRI findings of extradural and calvarial
changes: J-shaped sella (JSS), calvarial thickening, uni-/
bilateral tympanic effusion, concave remodeling of the
greater wings of the sphenoid bone (RGW), concave
remodeling of the cribriform plate of the ethmoid bone
(RCP), and internal hypertrophy of the occipitomastoid
sutures (IHOMS) uni-/bilaterally.
The study was approved by the Clinical Trials Ethics
Committee. All procedures were in accordance with the

DAMAR et al. / Turk J Med Sci
1964 Helsinki Declaration and its later amendments or
comparable ethical standards. Informed consent was
obtained from all parents of the individual participants in
the study.
2.1. Statistical analysis
MPS types and related cranial and MR findings were
presented as numbers and percentages.
Chi-square analysis was applied to assess the
relationship between the age groups of the patients with
type I, II, and VI diseases and the number of PVSEs in the
perisupraventricular white matter and corpus callosum,
and the relationship between IHOMS and other calvarial
findings, such as RGW and RCP and calvarial thickening.
SPSS 22.0 was used for the statistical analysis (IBM Corp.,
Armonk, NY, USA) and a value of P < 0.05 was considered
statistically significant.
3. Results
With the exception of one patient, all cranial MR studies
of the patients in the study exhibited some degree of
neuroimaging abnormalities.
Group I: The most frequent cranial intradural and
parenchymal MRI findings were WMSAs and PVSEs,
which were present in 51 (63%) and 39 (48%) of 80 patients,
respectively. There were also findings of parenchymal
atrophy (n = 33), hydrocephalus (n = 18), and uni-/
bilateral optic nerve sheath enlargement (n = 15) (Table 2).
No relationship was determined between the age
groups of the patients with type I, II, and VI diseases and
the number of PVSEs (P > 0.05).
Group II: The most frequent bone abnormalities
detected on the cranial MR scans were JSS and obliteration
of the mastoid air cells and/or the tympanic cavity with
mucosal inflammatory changes. These were determined in
45 (56%) and 44 (55%) of the 80 patients, respectively. The
other bone and soft tissue abnormalities observed were

RCP (n = 23), calvarial thickening (n = 18), uni-/bilateral
RGW (n = 11), and unilateral (n = 3) or bilateral (n = 9)
IHOMS (Table 3).
IHOMS was determined in 6 patients with MPS type
I, 4 with MPS type II, and 2 with MPS type VI. Although
there was no relationship between the IHOMS and other
calvarial findings, such as RCP or uni-/bilateral RGW in
the patients with type I, II, and VI diseases (P > 0.05),
the prevalence rate was high in MPS type I (n = 6, 54%).
There was no statistically significant association between
IHOMS and calvarial thickening.
Meckel’s cave invagination, pineal cysts, choroid plexus
cysts, posterior fossa arachnoid cysts, mega cisterna
magna, and cerebellar vermian hypoplasia were among the
other MRI findings encountered.
The cranial MRIs of a newly diagnosed 13-year-old
girl with type III MPS revealed no imaging abnormalities.
This patient had hyperactivity and mental retardation and
exhibited mild somatic features. She had been followed up
in the pediatric neurology department due to attention
deficit hyperactivity disorder and Rett syndrome for
several years before being admitted to the Pediatric
Metabolic Diseases Clinic.
4. Discussion
In the present study, the cranial MRIs of 80 MPS patients
with various disease types were evaluated. The patient data
were analyzed in terms of the radiopathological changes
described above.
The cranial imaging features of MPS and the
effectiveness of various treatment options have been
widely described in the literature [12–14].
In severe forms of MPS, CNS involvement is always
present and the resultant progressive neurodegeneration
may lead to the death of these patients in their first or
second decades. Patients with mild or moderate forms of

Table 2. MRI findings of intradural and parenchymal changes.
MPS type (n = 80)

PA

HC

WMSAs

PVSEs

ONSE

Type I (11)

8/11

5/11

10/11

9/11

1/11

Type II (14)

7/14

3/14

11/14

13/14

3/14

Type III (24)

13/24

6/24

16/24

8/24 *

1/24

Type IV (15)

1/15

1/15

2/15

0

3/15

Type VI (14)

2/14

3/14

10/14

9/14

7/14

Type VII (2)

2/2

0

2/2

0

0

Total

33/80

18/80

51/80

39/80

15/80

PA: Parenchymal atrophy, HC: Hydrocephalus, WMSAs: White matter signal
alterations, PVSEs: Perivascular space enlargements, *: number of total foci ≤ 5, ONSE:
Optic nerve sheath enlargement (unilateral or bilateral).
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Table 3. MRI findings of extradural and calvarial changes.
MPS type (n = 80)

JSS

CT

TE

RGW

RCP

IHOMS

Type I (11)

11/11

0

9/11

3/11

6/11

6/11

Type II (14)

11/14

1/14

9/14

3/14

6/14

4/14

Type III (24)

3/24

16/24

7/24

1/24

3/24

0

Type IV (15)

7/15

1/15

9/15

0

0

0

Type VI (14)

12/14

0

9/14

4/14

8/14

2/14

Type VII (2)

1/2

0

1/2

0

0

0

Total

45/80

18/80

44/80

11/80

23/80

12/80

JSS: J-shaped sella, CT: Calvarial thickening, TE: Tympanic effusion (unilateral or bilateral), RGW:
(Concave) remodeling of the greater wings (of the sphenoid bone), RCP: (Concave) remodeling of
the cribriform plate (of the ethmoid bone), IHOMS: Internal hypertrophy of the occipitomastoid
sutures. Note: Three of 12 patients have unilateral and the remaining patients have bilateral
IHOMS.

the disease live longer but the morbidity rates remain high.
Evident mental abnormalities are not expected in mildly
expressed forms of MPS I (e.g., in Hurler/Scheie diseases,
which show slowly progressive CNS involvement, and in
Scheie disease, which almost always exhibits no mental
retardation), MPS II (the attenuated phenotype shows no
mental deterioration and an intermediate form exhibits
slowly progressive CNS involvement), MPS III (a slowly
progressive form), MPS IV (Morquio disease), and MPS
VI (Maroteaux–Lamy disease) [15].
One of the most frequent abnormalities observed was
patchy or diffuse cerebral WMSAs that varied in form
and severity in different types of disease (n = 51, 63%).
These signal abnormalities have been reported to be due
to abnormal myelination and/or gliosis and they become
more evident during the course of the disease [16,17].
WMSAs were prominent in type I, II, and most of MPS type
III and VI patients in this series. The white matter regions
affected were mainly the posterior periventricular white
matter areas, and subcortical white matter areas were also
affected to a lesser extent. Diffuse periventricular WMSAs
in type III disease and patchy WMSAs in other types of
MPS have been previously reported [13]. The observations
of the current series were compatible with these findings.
However, the relationship of patchy or diffuse cerebral
WMSAs with clinical findings is a controversial issue in
the literature, but a positive association between the extent
of white matter lesions and duration of the disease has
been reported [18].
Perivascular space (also called the Virchow–Robin
space) enlargement (PVSE) was one of the most frequently
encountered findings in this series (n = 39, 48%). This
common but nonspecific feature may be seen in other
numerous diseases, as well as in healthy people. The
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prominent perivascular spaces are classically found to be
located in three brain regions: the inferior parts of the basal
ganglia, the centrum semiovale, and the midbrain. However,
when compared to healthy individuals, some gliotic foci
around the enlarged perivascular spaces are present in MPS
patients. PVSEs in MPS patients have been related to GAG
storage around the perivascular areas or leptomeninges, with
a resultant decrease in cerebrospinal fluid (CSF) absorption
[14,16,19]. In the current series, PVSEs were usually located
in the corpus callosum and/or posterior periventricular
white matter, with diameters mostly <10 mm. The patients
with MPS type I, II, and VI had a higher incidence of PVSEs.
No relationship was determined between the age groups of
these patients and the number of PVSEs. Although PVSE
was not a prominent feature of type III patients in this series,
≤5 foci were mostly determined in the corpus callosum in 8
of the 24 patients in this group. Furthermore, no PVSEs were
observed in type IV patients and in some of the patients with
other MPS types (Table 2). In a 15-year-old male patient with
type II MPS, PVSEs were more widespread and they were
located in the basal ganglia, in the thalamic regions, and in
the subcortical areas, resulting in an extensive cribriform
appearance of the brain parenchyma. This patient also had
patchy WMSAs extending towards the subcortical areas,
where the short association fibers (also called U-fibers) are
located (Figures 1a–1d). Although PVSEs may not develop
in some MPS patients, enlarged PVSs should be considered
as evidence for the diagnosis of MPS when accompanied
by other specific imaging findings, especially when these
are located in the corpus callosum [14]. A previous study
comparing patients with MPS and cognitive decline and
patients with MPS but without cognitive decline found no
significant difference between the groups in the frequency
of enlarged perivascular spaces [20].

DAMAR et al. / Turk J Med Sci

Figure 1. Coronal FLAIR (a, b) and sagittal T2 weighted (c, d) MR images demonstrate concave remodeling of
ethmoid roof (blue arrows) and greater wing of the sphenoid bone (red arrows). There is also a ‘J shaped sella’
form (on image c) shown with an orange arrow (15 years old, MPS II).

Parenchymal atrophy (n = 33, 41%) and communicating
hydrocephalus (n = 18, 22%) were the other two important
and significant features in this series. These findings were
especially prominent in type I, II, and particularly type
III patients (Table 2). In some of the patients with both
hydrocephalus and parenchymal atrophy, one of these
findings (either hydrocephalus or parenchymal atrophy)
was usually more prominent. Currently proposed reasons
for the mechanism of hydrocephalus development in
MPS patients include the presence of abnormal CSF
absorption and venous hypertension [13,14]. The systemic
accumulation of GAGs also affects the meninges and
impairs the function of arachnoid granulations, thereby
decreasing CSF reabsorption, and the abnormal bone
proliferation at the skull base decreases cerebral venous

outflow. One or both mechanisms lead to communicating
hydrocephalus. In the present study, one patient with type
VI MPS had noncommunicating hydrocephalus with
accompanying periventricular edema that resulted from
severe spinal narrowing at C1–2 levels. This patient had
undergone surgical treatment and is now progressing
well. In respect of hydrocephalus, not only was the
supratentorial ventricular system found to be affected in
the present study, but the peripheral CSF spaces were also
enlarged in some patients. Of these patients, especially
those with MPS type I had bitemporal subarachnoid space
enlargements and arachnoid cysts in the middle cranial
fossa, anterior to the temporal poles.
Of note, 2 patients with type I MPS in this study had the
signs of a cerebrovascular accident: an 8-month-old female
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patient, who was one of identical twins, had right middle
cerebral artery infarction with severe encephalomalacia of
the right cerebral hemisphere (Figures 2a–2c). The other
was a 16-month-old male patient with macrocephaly and
bifrontal subarachnoid space enlargements, who also had
a left frontal subdural hematoma, which may have resulted
from the vasculopathic changes that may be seen in these
patients (Figures 2d–2e) [21].
In the cranial MRI evaluations of the present study,
the most frequent bone abnormality was JSS (n = 45,
56%). This nonspecific finding may be seen as a normal
variant in healthy individuals but it may also be a sign of
some disease processes, such as chronic hydrocephalus,
optic glioma, osteogenesis imperfecta, achondroplasia,
neurofibromatosis, and MPS [22]. JSS has been described
in type I, II, IIIA, IV, and VI MPS and it is usually associated
with growth hormone deficiency (Figure 1c) [13].
The second most common bone abnormality was uni-/
bilateral mastoid inflammatory changes and tympanic
effusion (n = 44, 55%). Chronic otitis media may lead to
hearing loss in MPS patients [23].
Other findings include the concave remodeling of the
bones of the anterior and middle cranial fossae, resulting in
closed meningoencephaloceles [17]. RCP was determined
in 23 of the 80 patients in the present study (none with
type IV disease). Of the 23 patients with type I, II and VI
diseases, 11 also had uni-/bilateral RGW, and all of these
patients had meningeal pouches filled with CSF, with or
without accompanying cerebral parenchyma extending
into the cavity. In addition to the above-mentioned features,
there were millimetric leptomeningeal indentations in the
calvarium of some patients. Protrusion of the meninges
and CSF through the cavum trigeminale (Meckel’s cave),
also known as petrous apex cephaloceles, was seen in 9
patients. This condition has been related to the presence
of chronic intracranial hypertension [17]. In addition,
the MR myelography (maximum intensity projection)
and thoracolumbar MR scans of some MPS patients with
concave remodeling of the cranial bones showed that
bilateral lumbosacral perineural cysts were settled in the
intervertebral foramina, proximal to the posterior root
ganglia. This additional finding of lumbosacral perineural
cysts may support the above-mentioned theory proposing
the presence of chronic increase in pressure in different
CSF compartments of the CNS in these patients (Figure 3).
Progressive pseudoexophthalmos is another clinical
entity that has been reported to be associated with
MPS and it is characterized by the presence of shallow
orbits [11]. There is currently no generally accepted
pathophysiological model to explain this entity. It can
be considered that the concave remodeling, both in the
greater wings of the sphenoid bone and the cribriform plate
of the ethmoid bone, could be the cause of the observed
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pseudoexophthalmos in these patients. The greater wings
of sphenoid bone form the posterolateral parts of the orbit
and the presence of bone dysplasia may cause the globe
to be displaced anteriorly. In particular, in the inferior
orbital plane on axial images, the apical parts of the
orbits were observed to be narrowed mediolaterally, with
a sandglass appearance. This finding seems to be related
to the changes in the greater wings of the sphenoid bone
and to the lateral wall convexity of the enlarged ethmoid
sinus cells. The RCP also separates the right and the left
group of ethmoid sinus cells from each other and displaces
them laterally, thereby contributing to the narrowing
of the medial apical part of the orbits (Figures 4 and 5).
Another finding accompanying pseudoexophthalmos
appearance was extraconal fat tissue deposition anteriorly.
In a previous ophthalmology study, one of the sonographic
morphological changes was widening of the optic nerve
and its sheath in type I, II, and VI MPS patients. Increased
intracranial hypertension or meningeal GAG storage
were suggested to be the cause of the optic nerve sheath
enlargement [24,25]. This finding may also relate to
communicating hydrocephalus [14]. Widening of the
CSF space in the optic nerve sheath may contribute to
progressive pseudoexophthalmos. Distinct uni-/bilateral
optic nerve sheath enlargement was observed in 15 of the
80 MPS patients (Table 2). In only 3 of these 15 patients
was associated hydrocephalus observed. This result may be
due to the nonhomogeneous increase in pressure in the
CSF compartments.
In younger patients, who were diagnosed and imaged
in the early course of the disease, some of the mentioned
features were not prominent. In the MRI studies of 20
patients who were younger than 3 years old, neither
significant RGW nor RCP was determined. This finding
suggests that some of the changes related to the cranial
bone morphology are more likely to develop in the later
course of the disease.
Another calvarial finding is IHOMS. The presence
of this finding was evaluated by the consensus of two
experienced radiologists. This feature was detected
unilaterally (n = 3) or bilaterally (n = 9) in 12 patients,
most of whom had MPS type I (n = 6, 54%) (Table 3;
Figures 6–8). There are some comments about different
posterior fossa findings but this bone peculiarity has
never been mentioned in the literature [13,14,17,26]. As
discussed above, although remodeling of the cranial bones
was encountered in later processes of the disease, most of
the IHOMS were detected in younger patients. Five of the
6 patients with MPS type I, 3 of the 4 patients with MPS
type II, and both of the patients with MPS type VI were
younger than 3 years old. This finding may be related to
early cranial suture involvement and GAG deposition. A
previous study described that the majority of MPS patients
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Figure 2. 3-D MR angiography images in 2 planes (a) show the absence of right middle cerebral artery (MCA) and right anterior
cerebral artery (ACA) flows. Other polygon arteries including the right carotid artery have irregular outlines and focal-segmental
stenosis. Diffusion weighted imaging (DWI, B = 1000) (b) and apparent diffusion coefficient (ADC) (c) map images demonstrate a
large acute infarction in the right MCA territory (One of 8-month-old twin siblings, MPS type I). Axial T2 (d) and T1 (e) weighted MR
images reveal that there is an old subdural hemorrhage anterior to the left frontal lobe (black arrow). There are also bilateral choroid
plexus cysts (asterisks) (16 months old, MPS type I).
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Figure 3. Sagittal T2 weighted MR image (a) and 3-D MR myelography (b) demonstrate multilevel lumbosacral perineural cysts settled
in the intervertebral foramina (white arrows) (17 years old, MPS type II).

Figure 4. A 3-D illustration orbit of a MPS patient to depict
the possible mechanism of pseudoexophthalmos. Sandglass
appearance of the orbital apex due to concave remodeling
of cribriform plate (white asterisks) and greater wing of the
sphenoid bone (red asterisks).

1056

have premature fusion of the cranial sutures [27]. In the
present study, none of the patients were evaluated for
craniosynostosis. On the other hand, the patients with
unilateral IHOMS did not exhibit any posterior cranial
deformation suggesting craniosynostosis. According
to our observations, this abnormality may be evident
with horn-shaped morphology in some MPS patients.
There was no significant relationship between calvarial
thickening and IHOMS.
Calvarial thickening with enlargement of diploe spaces
was one of the most frequent bone findings in MPS type
III patients (16/24 patients, 66%; in all subtypes) [13]. The
coarse appearance of the sphenoid body without sinus
pneumatization, narrowing of the sella turcica, thick and
white (due to presence of fatty bone marrow) sail-shaped
crista galli in sagittal T1-weighted images, and lack of
pneumatization in bilateral mastoid apex and/or paranasal
sinuses were the other evident bone findings that may help
to distinguish type III MPS from the other types (Figure 9).
Together with the clinical and radiological findings, the
diagnosis of MPS is possible with quantitative detection
of elevated urinary GAG levels. Further studies to detect
the specific enzyme deficiencies and genetic analyses are
performed to specify the disease type [1,6,28].
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Figure 5. Axial T1 weighted MR image (a) depicts that the orbital apex is narrowed bilaterally and formed as a sandglass appearance
(white arrows). Axial T1 weighted MR image (b) reveals bilateral exophthalmos (white dotted line) (15 years old, MPS type II).

Figure 6. Axial FLAIR (a) and T1 weighted MR images (b–f) show unilateral or bilateral IHOMs (white arrows) of 6 different patients
with MPS type I. Note: MRIs shown in a and b belong to twin siblings. (a: 8 months old, b: 8 months old, c: 13 months old, d: 4 years
old, e: 16 months old, f: 23 months old).
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Figure 7. Axial T2 weighted (a–c) and T1 weighted (d) MR images show unilateral or bilateral IHOMs (white
arrows) of 4 different patients with MPS type II. (a: 14 months old, b: 15 months old, c: 4 years old, d: 8 months
old).

Bone marrow transplantations, peripheral blood
hematopoietic cell transplantations, umbilical cord blood
transplantations, and intravenous/intrathecal enzyme
replacement therapies (ERTs) are currently used in the
treatment of MPS. ERTs have been used for type I, II,
IV, and VI diseases and the production of new enzyme
samples has been announced recently for the treatment of
type VII disease; studies are still being performed on the
use of ERT for type III disease [3,9,12,29]. These treatment
options may change the course of the disease and prolong
life expectancy, meaning that radiologists may encounter
older MPS patients more frequently in the future [9].
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There were some limitations of the present study.
First, it was a retrospective study and most of these
patients had only one MR evaluation and some were
lost during follow up. Therefore, there are no specific
treatment-related changes in these findings mentioned
above, although our center was able to provide treatment
for some of the patients who had type I, II, and VI
diseases. Second, since some different MRI machines
had been used to perform the cranial scans in the present
study, the images evaluated were of varying quality,
and so the comparability between the MRI images of
patients was somewhat limited. Third, there was no
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Figure 8. Axial T2 (a-b) weighted MR images show bilateral IHOMs (white arrows) of 2 different patients with
MPS type VI. (a: 26 months old, b: 18 months old).

Figure 9. Sagittal T1 weighted MR image shows diffuse calvarial
thickening. Note that the lack of pneumatization in frontal
and sphenoid sinuses. Hyperintense crista galli has an evident
hypertrophic appearance like a white sail (white dotted arrow) (17
years old, MPS type IIIc).

1059

DAMAR et al. / Turk J Med Sci
three-dimensional constructive interference in steadystate (3D-CISS) studies in cases of ventriculomegaly,
arachnoid cysts, and pseudomeningoceles. Fourth, in
some patients, because of the difficulties in obtaining
quantitative measurements, it was relatively difficult to
define hydrocephalus coexistence with cerebral atrophy.
Fifth, the skull radiographs were not evaluated for
craniosynostosis. Finally, most of MPS subtypes were
not known and comparison of the features could not be
performed.

In conclusion, the cranial MRIs of MPS patients
frequently exhibit abnormal features. These features
may provide diagnostic clues to differentiate the type of
the disease in radiological imaging. IHOMS is presented
here as a new imaging feature and could also be a helpful
finding for diagnosis. Nevertheless, there is a need for
further studies of large MPS series to confirm this finding.
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